Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus VITRAKVI.
NILOTINIB HYDROCHLORIDE DIHYDRATE vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nilotinib is a BCR-ABL tyrosine kinase inhibitor that binds to and stabilizes the inactive conformation of the ABL kinase domain, thereby inhibiting proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
400 mg orally twice daily, approximately 12 hours apart, without food (at least 2 hours before or 1 hour after a meal).
100 mg orally twice daily
None Documented
None Documented
Approximately 17 hours (terminal elimination half-life; supports once-daily or twice-daily dosing; extensive accumulation with daily dosing, steady state by day 8)
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Fecal (93%), renal (3%; unchanged nilotinib appears minimal, mostly metabolites)
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor